UTHRUnited Therapeutics Corporation
What is the market doing?
No clear lean: rangebound and insiders net selling (often routine).
Choppy, but holding above its 200-day average. Price is +5% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Moderately shorted, settled Sep 15, 2026, about a week of normal trading to cover. Up 36% since the previous count, up from 4.3% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How UTHR is trading
United Therapeutics Corporation is +32% over the past year while the S&P 500 is +18%: 13 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +5.0%
vs 200-day average · close to trend
- RSI (14)
- 64
RSI (14) · neutral
- Below its 52-week high
- 7.9%
Below its 52-week high
Details›
- Last close2026-10-09
- $549.48
- 1 monthS&P 500 +2.7%
- +9.0%
- 1 yearS&P 500 +18%
- +32%
- 5 yearsS&P 500 +88%
- +164%
- vs 50-day average$512.71
- +7.2%
- 52-week high
- $596.76
- 52-week low
- $414.73
- Annualised volatility
- 42%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$265K
| Year | Return |
|---|---|
| 2026 (year to date) | +13% |
| 2025 | +38% |
| 2024 | +60% |
| 2023 | −21% |
| 2022 | +29% |
| 2021 | +42% |
| 2020 | +72% |
| 2019 | −19% |
| 2018 | −26% |
| 2017 | +3.2% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 4 of 10 | +0.76% |
| Feb | 10 | 5 of 10 | −2.4% |
| Mar | 10 | 4 of 10 | −1.1% |
| Apr | 10 | 4 of 10 | +1.3% |
| May | 10 | 4 of 10 | +1.6% |
| Jun | 10 | 6 of 10 | +1.7% |
| Jul | 11 | 5 of 11 | +1.4% |
| Aug | 11 | 7 of 11 | +3.3% |
| Sep | 11 | 4 of 11 | +0.22% |
| Oct | 11 | 9 of 11 | +5.4% |
| Nov | 10 | 7 of 10 | +5.9% |
| Dec | 10 | 5 of 10 | +3.1% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers, Specialty & Generic
Ranks #2 of 41 by RyuScore